Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies

0 avis

Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies

Archive ouverte

Edité par CCSD ; Oxford University Press (OUP) -

International audience. No abstract available

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Persistent COVID-19 in an immunocompromised host treated by SARS-CoV-2-specific monoclonal antibodies

Archive ouverte | Bailly, Benoit | CCSD

International audience

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Archive ouverte | Mansi, Laura | CCSD

International audience. Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive e...

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Archive ouverte | Kroemer, Marie | CCSD

International audience. Adaptive Immune responses generated by SARS-CoV-2 virus in convalescent patients according to disease severity remain poorly characterized. To this end, we designed a prospective study (NCT04...

Chargement des enrichissements...